TAKE-HOME MESSAGE
In this retrospective cohort study of 4023 patients aged ≥66 years with classical Philadelphia chromosome–negative myeloproliferative neoplasms (MPN), there was no significant difference in the incidence of solid or hematologic second malignancies in patients treated with hydroxyurea compared with those not treated with hydroxyurea.This result suggests that, among older patients with MPN, the use of hydroxyurea is not associated with an increased risk of second malignancies.
Published in Benign HematologyJournal Scan / Research · August 09, 2022